Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Johnson & Johnson's $3.05 billion Halda bet is already paying off in the clinic.
By Prosper Junior Bakiny -- Nov 19, 2026 at 6:45PM EST
Key Points
- Johnson & Johnson's JNJ-6143 posted excellent results in an early-stage clinical trial.
- For income investors, the real story is a Dividend King with a deep lineup and pipeline.
Last year, Johnson & Johnson (JNJ -2.04%) acquired a smaller biotech, Halda Therapeutics, in a cash transaction valued at $3.05 billion. The key asset from that transaction was JNJ-6143, an investigational, early stage candidate for prostate cancer. It will take time to determine whether this acquisition was worth it for Johnson & Johnson, but recent clinical developments suggest that the $3.05 billion the pharmaceutical giant spent may have been well spent. Let me explain.
Image source: The Motley Fool.
Impressive clinical trial results
JNJ-6143 is part of an experimental class of cancer medicines called Regulated Induced Proximity Targeting Chimera, which use proteins found in cancer cells to disrupt certain functions those cells need to survive. This approach could lead to much stronger efficacy than existing standards of care for certain cancers. Johnson & Johnson's JNJ-6143 showed the potential of these therapies in a Phase 1 clinical trial, the results of which it presented at the European Society for Medical Oncology 2026 Congress, held in Madrid in October.
The medicine was tested in patients with metastatic castration-resistant prostate cancer. Notably, these patients had received a median of four prior therapies, so we aren't dealing with an easy-to-treat cancer. Yet, JNJ-6143 performed extremely well. It led to an overall response rate (the percentage of patients who respond to treatment) of 75% among patients with measurable disease. This data is highly encouraging. Of course, this was only an early stage study. There is a long road ahead before JNJ-6143 earns approval, that is, if it performs well in future clinical studies.
However, this once again highlights the strength of Johnson & Johnson's pipeline. The company has successfully expanded its lineup of approved drugs in recent years, with newer launches such as Imaavy, which treats generalized myasthenia gravis, and Icotyde, a therapy for plaque psoriasis.
These newer launches could help the company overcome headwinds, such as government-led drug price negotiations and patent cliffs, that it will face over the medium term. Over the next five years, Johnson & Johnson should make significant progress across its pipeline, including with JNJ-6143. Johnson & Johnson's innovative abilities are one of the key reasons the stock is attractive.
And it's worth noting that the company's innovative medicines division could perform even better over the long run, given that it has spun off its slower-growing consumer health division and can focus more on its higher-growth pharmaceutical business. Johnson & Johnson's medtech unit adds even more depth and diversification to the business.
Finally, Johnson & Johnson remains one of the best dividend stocks on the market. With its streak of 64 consecutive years of payout increases, the healthcare leader is a Dividend King, or a stock with 50 or more straight annual dividend increases. Income seekers should stick with this stock for the long term.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

2 Financial Stocks to Buy Near Their 52-Week Lows

Cryptocurrency Market Plummets, Bitcoin Falls Below $56,000

Wall Street Fear Index Soars as Bitcoin Approaches a Key Bottom

Opinion: The $6 trillion evaporation of the US stock market in 45 days is not the burst of the AI bubble; a bottom-fishing rebound in April 2025 may reoccur

Variational’s $1.5 billion trading business has a catch even profitable traders cannot escape

DWF Labs: Bitcoin is Not Digital Gold, It Follows the Nasdaq

Fidelity Executive Says Bitcoin's Correlation with S&P 500 is Rising

Strategy Investor Relations Head Says Anthropic IPO is a Catalyst for Bitcoin Pullback

Where Will Bloom Energy Stock Be in 5 Years After More Than Doubling Its Revenue in 2026?

Walmart stock rises 162% in five years, P/E ratio at 46.5

US Data Center Construction Costs Surge 13% in 2026

Costco Just Made a New All-Time High After Announcing a $30-Per-Share Special Dividend. Is the Stock a Buy Before Dec. 10?

Bank of America Analyst: The Trend of Risk Assets in 2027 Will Depend on Two Key Questions

The 1 Unstoppable ETF I'd Buy Today and Hold for Decades

Société Générale Predicts S&P 500 Will Rise to 8500 Points by End of 2027

Prediction: Nvidia Will Hit a New All-Time High in 2027 (Hint: Watch This Metric)

Novo Nordisk Reports 4.6% Dividend Yield Amid Growth Prospects

TS Lombard Warns of 2000 Similarities in Technology Stocks

Industrial Bank Expects End of U.S. Stock Market Valuation Adjustment Cycle by 2027

Why Bending Spoons May Choose to Issue Convertible Bonds Next

Mr&强 Shares WEEX GTA6 Style AI Demo Event

Copper Prices Drop to Seven-Month Low, But AI Infrastructure Companies May Face Rising Costs

Tencent Releases Hy4 Model Weights, Supporting One Million Token Context

Mitsui & Co. Subsidiary Launches Digital Bond Business for Individuals, First Offering is a 1-Year Bond

Bank of America Says U.S. Treasury Yields Rise Driven by Safe-Haven Demand

Options Overview | AMD Sees $37.88 Million in Forward Double Call Sell, Limited Upside Ahead; Intel Shows Large Put Buys Indicating Bearish Dominance

Samsung Electronics Annual Personnel Adjustment, Two Executives Retain Their Positions

Tom Lee: Market Decline Due to Panic, Abandoning is Like Selling at a Low Point

2 Reasons to Buy SpaceX (SPCX) Stock -- and 1 Reason to Wait










